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Summary 
Background India accounts for a disproportionate burden of global childhood illnesses. To inform policies and 
measure progress towards achieving child health targets, we estimated the annual national and state-specific 
childhood mortality and morbidity attributable to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) 
between 2000 and 2015.
Methods In this modelling study, we used vaccine clinical trial data to estimate the proportion of pneumonia deaths 
attributable to pneumococcus and Hib. The proportion of meningitis deaths attributable to each pathogen was derived 
from pathogen-specific meningitis case fatality and bacterial meningitis case data from surveillance studies. We applied 
these proportions to modelled state-specific pneumonia and meningitis deaths from 2000 to 2015 prepared by the WHO 
Maternal and Child Epidemiology Estimation collaboration (WHO/MCEE) on the basis of verbal autopsy studies from 
India. The burden of clinical and severe pneumonia cases attributable to pneumococcus and Hib was ascertained with 
vaccine clinical trial data and state-specific all-cause pneumonia case estimates prepared by WHO/MCEE by use of risk 
factor prevalence data from India. Pathogen-specific meningitis cases were derived from state-level modelled pathogen-
specific meningitis deaths and state-level meningitis case fatality estimates. Pneumococcal and Hib morbidity due to 
non-pneumonia, non-meningitis (NPNM) invasive syndromes were derived by applying the ratio of pathogen-specific 
NPNM cases to pathogen-specific meningitis cases to the state-level pathogen-specific meningitis cases. Mortality due to 
pathogen-specific NPNM was calculated with the ratio of pneumococcal and Hib meningitis case fatality to pneumococcal 
and Hib meningitis NPNM case fatality. Census data from India provided the population at risk.
Findings Between 2000 and 2015, estimates of pneumococcal deaths in Indian children aged 1–59 months fell 
from 166 000 (uncertainty range [UR] 110 000–198 000) to 68 700 (44 600–86 000), while Hib deaths fell from 
82 600 (52 300–112 000) to 15 600 (9800–21 500), representing a 58% (UR 22–78) decline in pneumococcal deaths and an 
81% (59–91) decline in Hib deaths. In 2015, national mortality rates in children aged 1–59 months were 56 (UR 37–71) 
per 100 000 for pneumococcal infection and 13 (UR 8–18) per 100 000 for Hib. Uttar Pradesh (18 900 [UR 12 300–23 600]) 
and Bihar (8600 [5600–10 700]) had the highest numbers of pneumococcal deaths in 2015. Uttar Pradesh 
(9300 [UR 5900–12 700]) and Odisha (1100 [700–1500]) had the highest numbers of Hib deaths in 2015. Less conservative 
assumptions related to the proportion of pneumonia deaths attributable to pneumococcus indicate that as many as 
118 000 (UR 69 000–140 000) total pneumococcal deaths could have occurred in 2015 in India. 
Interpretation Pneumococcal and Hib mortality have declined in children aged 1–59 months in India since 2000, even 
before nationwide implementation of conjugate vaccines. Introduction of the Hib vaccine in several states 
corresponded with a more rapid reduction in morbidity and mortality associated with Hib infection. Rapid scale-up 
and widespread use of the pneumococcal conjugate vaccine and sustained use of the Hib vaccine could help accelerate 
achievement of child survival targets in India.
Funding Bill & Melinda Gates Foundation.
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Introduction
Streptococcus pneumoniae (pneumococcus) and Haemo­
philus influenzae type b (Hib) are serious causes of pneu­
monia, meningitis, and other severe childhood infections 
in India and worldwide.1 Highly efficacious vaccines 
that provide protection from these pathogens have been 
used in developed and developing countries for many 
years; global data on vaccine introduction and vaccine 
programme implementation can be visualised on 
VIEW­hub, an interactive platform developed by the 
International Vaccine Access Center (IVAC). The Hib­
containing pentavalent vaccine was introduced in the 
immunisation programmes of Tamil Nadu and Kerala in 
December, 2011.2 It is now used in the routine 
immun isa tion programme of all states in India. The 
13­valent pneumococcal conjugate vaccine (PCV) was 
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introduced subnationally in 2017. There are plans to expand 
its use in India in the coming years.
Efforts to improve access to primary maternal and child 
health services in India have contributed to progress 
towards reducing child mortality. Many of these efforts 
have been concentrated in less socioeconomically 
developed states, including those that comprise the 
Empowered Action Group (EAG). Although India narrowly 
missed the Millennium Development Goal child mortality 
target of 44 deaths per 1000 livebirths by 2015,3 imple­
mentation and widespread use of new child health 
interventions, including new vaccines that protect children 
from some of the leading causes of mortality, could 
accelerate achievement of the Sustainable Development 
Goal of 25 child deaths per 1000 livebirths or lower in India 
by 2030. Since around 20% of child deaths occur in India, 
global progress towards reducing child mortality will 
depend on progress in India.
Disease burden is an important decision­making factor 
for the introduction and sustained use of new vaccines. 
The technical challenges associated with doing observa­
tional surveillance studies for pneumococcal and Hib 
infections in resource­poor settings have been extensively 
documented.4,5 Models can provide comple mentary insight 
into disease burden when observational studies are absent, 
inconsistent, or unable to provide such information for 
epidemiological reasons. For large and diverse countries 
such as India, subnational disease burden estimates are 
particularly important for policy making and programme 
planning, as national burden estimates can mask sub­
stantial variation in morbidity and mortality across large 
subnational populations.
Researchers have estimated that there were around 
105 000 deaths from pneumococcal pneumonia and 
564 000 cases of severe pneumococcal pneumonia in 
2010 in children younger than 5 years in India.6 There are 
no published subnational burden estimates for clinical 
pneumococcal pneumonia, pneumococcal meningitis, 
or other invasive pneumococcal diseases. There are also 
no published subnational burden estimates for Hib 
infection. In light of widespread Hib vaccine use, the 
anticipated expansion of PCV use in India, and reduct­
ions in all­cause mortality since 2010, we aimed to pre­
pare state­level pneumococcal and Hib disease burden 
estimates for India from 2000 to 2015.
Methods
Overview
In this modelling study, we estimated the pathogen­
specific burden in children aged 1–59 months at the state 
level separately for each of the three clinical syndromes 
associ ated with pneumococcus and Hib (ie, pneumonia, 
men ingitis, and invasive non­pneumonia, non­meningitis 
[NPNM]) using methods briefly described here and in 
detail elsewhere.1 NPNM is characterised by the isolation 
of pneumococcus or Hib from normally sterile body fluid 
but without the clinical findings of pneumonia or menin­
gitis. Input data for each model are described in table 1.7–15
As previously reported,1 we updated a systematic review 
of pneumococcal and Hib invasive disease16 with 
published and unpublished data up to and including 
2014 for the pathogen­specific meningitis and NPNM 
models. We searched six global databases (ie, PubMed, 
Embase, Biosis, Cochrane, Global Health, and Pascal) 
and five regional databases (ie, IMEMR, IMSEAR, 
LILACS, WHOLIS, and WPRIM) and followed the same 
quality assessment criteria described in the original 
literature review.16
Research in context
Evidence before this study
We searched PubMed for national and subnational estimates of 
pneumococcal and Haemophilus influenzae type b (Hib) morbidity 
and mortality in children in India from 2000 to 2017. Estimates 
of national pneumococcal and Hib morbidity and mortality for 
2000 were published in 2009 by the Child Health Epidemiology 
Reference Group (CHERG) collaboration (now the WHO Maternal 
and Child Epidemiology Estimation collaboration). Subnational 
estimates of pneumococcal pneumonia morbidity and mortality 
for India in 2010 were published in 2015. Based on these 
estimates, there were approximately 564 000 cases of 
pneumococcal pneumonia and 105 000 deaths from 
pneumococcal pneumonia in 2010. No subnational disease 
burden estimates for Hib were identified in the literature.
Added value of this study
We present, to our knowledge, the first comprehensive 
subnational estimates of pneumococcal and Hib morbidity and 
mortality in children aged 1–59 months in India, due to all 
syndromes associated with these pathogens (ie, pneumonia, 
meningitis, and other invasive diseases). This study is also the 
first to report on the annual subnational pneumococcal and Hib 
disease burden from 2000 to 2015. These estimates are based 
on recently published subnational cause of death estimates for 
India and incorporate new data from 67 studies published 
between 2006 and 2014, including three studies from India. 
These studies report on pathogen-specific meningitis case 
fatality and the distribution of meningitis case estimates by 
cause. Our pneumococcal and Hib meningitis morbidity and 
mortality models used updated methods that are based on 
estimates of all-cause meningitis deaths. The methods used in 
this study differ from previously published subnational 
pneumococcal disease burden estimates.
Implications of all the available evidence
Our estimates provide insight into progress towards reducing 
the morbidity and mortality associated with these two 
pathogens in young children. These data can be used to inform 
policies around expanded use of the pneumococcal conjugate 
vaccine in India.
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All analyses were done with Stata, version 14. Our 
analyses are compliant with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
statement (appendix p 4).17
Pathogen-specific pneumonia model
To estimate pathogen­specific pneumonia deaths and 
cases, we applied estimates of the proportion of pneu­
monia deaths and cases attributable to each pathogen to 
all­cause pneumonia mortality and morbidity estimates. 
All­cause pneumonia deaths and cases were prepared by 
the WHO Maternal and Child Epidemiology Estimation 
collaboration (WHO/MCEE). State­level all­cause pneu­
monia deaths were modelled for each year (2000–15) 
with verbal autopsy data from India.7 State­level, all­cause 
clinical, and severe pneumonia cases were prepared for 
2000 and 2015 with a previously described risk factor 
prevalence model (appendix pp 10–12).8
We used data from randomised controlled vaccine 
trials with various pneumonia endpoints in the probe 
approach to estimate the attributable fraction for each 
pathogen.1 Since PCV and Hib vaccine trials did not 
assess vaccine efficacy against pneumonia mortality, we 
used efficacy against radiograph­confirmed, primary 
See Online for appendix
Sources of data from India Sources of data from outside India or approach for 
missing data, or both
Pathogen-specific pneumonia
All-cause pneumonia deaths Modelled estimates based on verbal autopsy studies 
from India7
NA
Pneumonia cases Modelled estimates based on risk factor prevalence data 
from India8
NA
Proportion of pneumonia cases and 
deaths attributable to each pathogen
NA Used global estimate with clinical trial data1
Pathogen-specific meningitis
All-cause meningitis deaths* Modelled estimates based on verbal autopsy studies 
from India7
NA
Proportion of meningitis cases 
attributable to each pathogen
Meningitis surveillance: 2 studies9,10 Meningitis surveillance from Asia: 33 studies†
Pneumococcal meningitis CFR Pneumococcal meningitis surveillance from 
low mortality settings: NA; medium mortality settings: 
NA; high mortality settings: NA, very high mortality 
settings: NA 
Pneumococcal meningitis surveillance from low mortality 
settings: 36 studies; medium mortality setting: 13 studies; 
high mortality settings: 8 studies; very high mortality 
settings: 7 studies
Hib meningitis CFR Hib meningitis surveillance from low mortality settings: 
NA; medium mortality settings: 2 studies;11,12 
high mortality settings: 1 study;13 very high mortality 
settings: NA
Hib meningitis surveillance from low mortality settings: 
31 studies; medium mortality settings: 16 studies; 
high mortality settings: 4 studies; very high mortality 
settings: 10 studies 
Pathogen-specific NPNM
Pneumococcal NPNM case multiplier Severe pneumococcal disease surveillance from low or 
medium mortality settings: NA; high or very high 
mortality settings: 2 studies;14,15 non-severe 
pneumococcal disease surveillance: NA
Severe pneumococcal disease surveillance from low or 
medium mortality settings: 26 studies; high or very high 
mortality settings: 4 studies; non-severe pneumococcal 
disease surveillance: 2 studies
Hib NPNM case multiplier Hib disease surveillance from low or medium mortality 
settings: NA; high or very high mortality settings: NA
Hib disease surveillance from low or medium mortality 
settings: 26 studies; high or very high mortality settings: 
3 studies
Pneumococcal NPNM CFR multiplier Pneumococcal disease surveillance: NA Pneumococcal disease surveillance: 2 studies
Hib NPNM CFR multiplier Hib disease surveillance: NA Hib disease surveillance: 5 studies
Population at risk and demographic model parameters
Child mortality Unpublished modelled data based on SRS data from 
India
NA
Child population 2001 and 2011 India census data Interpolated and extrapolated with annual census growth 
rates estimates
Access to care for meningitis NFHS 2, 3, and 4‡ Linear interpolation and extrapolation
HIV prevalence UNAIDS unpublished data Apportioned HIV burden to states based on population
Hib vaccine coverage Inferred from DTP3 coverage estimates from AHS, DLHS, 
and NFHS
Linear interpolation or extrapolation
NA=not available. CFR=case fatality ratio. NPNM=non-pneumonia, non-meningitis. Hib=Haemophilus influenzae type b. SRS=Sample Registration System. NFHS=National 
Family and Household Survey. DTP3=third dose of diphtheria-tetanus-pertussis vaccine. AHS=Annual Health Survey. DLHS=District Level Household Survey. *All-cause 
meningitis cases and all-cause NPNM cases and deaths are not used; pathogen-specific meningitis cases and pathogen-specific NPNM cases and deaths are based on 
pathogen-specific meningitis deaths. †Full list of citations for non-Indian studies provided in the appendix (pp 5–9). ‡Used data from question related to care seeking for 
pneumonia symptoms as a proxy for care seeking for meningitis.
Table 1: State-specific model parameters and sources
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end point pneumonia as a proxy for this value. The 
efficacy values against clinical and severe pneumonia 
were used to estimate pathogen­specific pneumonia 
morbidity.
PCV and Hib vaccines do not prevent all pneumonia 
deaths or cases caused by pneumococcus and Hib, and 
so additional adjustments to vaccine efficacy values are 
required. To account for incomplete vaccine efficacy, the 
observed efficacy against vaccine­type invasive pneumo­
coccal disease was used as a proxy for the efficacy against 
vaccine­type pneumococcal pneumonia. Efficacy for 
vaccine­type pneumococcal pneumonia has not been 
measured in childhood PCV efficacy trials. PCV efficacy 
values were also adjusted to account for the proportion of 
vaccine­type invasive pneumococcal disease in the control 
group and for Hib vaccine use, since all trials were done in 
settings with routine use of this vaccine. Parameters used 
for these adjustments are unique to each study, and so we 
made these adjustments for each trial before combining 
estimates across trials in random­effects meta­analyses. 
Given the uncertainty around the proportion of pneum­
onia deaths attributable to pneumococcus, we applied the 
same sensitivity analyses used in the estimation of global 
pneumococcal pneumonia deaths.1
The primary source of uncertainty in this approach is 
the between­study variability in vaccine efficacy estimates. 
Therefore, uncertainty bounds for the pathogen­specific 
pneumonia mortality and morbidity model were based on 
a jackknife analysis, in which one study is omitted from 
the analysis at a time, for the upper and lower bounds of 
the pneumococcal and Hib pneumonia fractions.1 Other 
sources of uncertainty were not included in the pneumonia 
mortality and morbidity models.
Pathogen-specific meningitis model
Pathogen­specific meningitis deaths for each state were 
estimated by applying the proportion of meningitis deaths 
caused by pneumococcus and Hib to all­cause meningitis 
deaths prepared by the WHO/MCEE collaboration. We 
estimated the proportion of meningitis deaths attributable 
to each pathogen in each state using summary estimates 
of the proportion of meningitis cases attributable to each 
pathogen and adjusted pathogen­specific meningitis case 
fatality ratios (CFR), both from values reported in the 
literature (appendix pp 5–9). Reported CFR estimates 
represent only children with access to care. Therefore, we 
adjusted state pathogen­specific meningitis CFR estimates 
using data from the National Family and Household 
Survey (NFHS) on the proportion of children seeking care 
for pneumonia symptoms, as a proxy for care seeking for 
meningitis (table 1). For years missing access to care 
values, we assumed linear trends between available 
values. A 5­year moving average was used to smooth 
pathogen­specific CFR estimates within states. State 
pathogen­specific meningitis mortality estimates were 
divided by pathogen­specific meningitis CFR estimates to 
derive pneumococcal and Hib meningitis morbidity 
estimates.
We followed previously published methods for ascer­
taining uncertainty bounds for meningitis morbidity and 
mortality; we ascertained the most conservative (ie, widest) 
uncertainty for aetiological proportions based on a 
jackknife, leave­one­study­out analysis and the reported 
confidence intervals from the random­effects meta­
analysis.1 As with the pneumonia models, uncertainty for 
the meningitis mortality and morbidity models did not 
account for other sources of uncertainty.
Pathogen-specific invasive non-pneumonia, 
non-meningitis model
We used previously described methods to estimate 
pathogen­specific morbidity from other NPNM invasive 
States
Central Chhattisgarh, Madhya Pradesh, Rajasthan, and Uttar Pradesh
East Bihar, Jharkhand, Odisha, and West Bengal
North Chandigarh, Delhi, Haryana, Himachal Pradesh, Jammu and Kashmir, Punjab, and 
Uttarakhand
Northeast Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Sikkim, and 
Tripura
South Andaman and Nicobar Islands, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, 
Puducherry, and Tamil Nadu
West Dadra and Nagar Haveli, Daman and Diu, Goa, Gujarat, and Maharashtra
Empowered Action 
Group and Assam
Assam, Bihar, Chhattisgarh, Jharkhand, Madhya Pradesh, Odisha, Rajasthan, Uttar 
Pradesh, and Uttarakhand
Table 2: Indian states by region
Figure 1: Mortality rates for Streptococcus pneumoniae and Haemophilus influenzae type b for 2000–15, by 
region and EAG status*
EAG=Empowered Action Group. *EAG states: Bihar, Chhattisgarh, Jharkhand, Madhya Pradesh, Odisha, Rajasthan, 
Uttarakhand, and Uttar Pradesh. Assam was included with EAG states in this analysis. 
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syndromes (eg, sepsis).1 Briefly, we abstracted from 
published studies the ratio of pathogen­specific NPNM 
cases to pathogen­specific meningitis cases, stratified 
them by all­cause child mortality, and within those strata 
we combined ratios using random­effects meta­analyses. 
For each state, we applied the mortality­specific ratio 
from the meta­analysis to the pneumococcal or Hib 
meningitis cases estimates to infer the pathogen­specific 
NPNM cases. Pneumococcal NPNM cases were stratified 
by severe and non­severe cases by use of different 
NPNM case definitions from published studies. 
Pathogen­specific NPNM deaths were estimated with 
the ratio of pathogen­specific meningitis CFR to 
pathogen­specific NPNM CFR from the literature and by 
applying this value to pathogen­specific NPNM cases. 
Uncertainty ranges for pathogen­specific NPNM 
NPNM deaths 
(UR)
NPNM 
mortality 
rate (UR)
Meningitis 
deaths (UR)
Meningitis 
mortality 
rate (UR)
Pneumonia 
deaths (UR)
Pneumonia 
mortality 
rate (UR)
Total 
pneumococcal 
deaths (UR)
Total 
pneumococcal 
mortality rate 
(UR)
States
Andhra Pradesh 200 
(100–500)
4 (2–7) 300 
(100–500)
4 (2–8) 1800 
(1300–1900)
28 (20–29) 2300 
(1500–2900)
36 (23–45)
Assam 500 
(200–900)
13 (5–27) 500 
(200–1100)
14 (6–30) 3400 
(2400–3500)
97 (69–101) 4400 
(2800–5500)
124 (79–158)
Bihar 900 
(400–1800)
6 (3–12) 1000 
(500–2000)
7 (3–14) 6700 
(4700–6900)
46 (33–48) 8600 
(5600–10 700)
60 (39–74)
Chhattisgarh 200 
(90–400)
7 (3–14) 200 
(100–400)
8 (4–16) 1500 
(1000–1500)
53 (38–55) 1900 
(1200–2400)
68 (44–86)
Delhi <100 2 (1–5) <100 3 (1–5) 200 
(200–200)
15 (11–16) 300 
(200–400)
21 (13–26)
Goa <100 <1 (0–0) <100 0 (0–1) <100 2 (1–2) <100 2 (1–3)
Gujarat 300 
(100–600)
5 (2–10) 400 
(200–700)
6 (3–11) 2300 
(1600–2400)
38 (27–40) 2900 
(1900–3600)
49 (32–61)
Haryana 200 
(100–300)
7 (3–12) 200 
(100–400)
8 (4–14) 1200 
(900–1300)
47 (34–49) 1600 
(1000–1900)
62 (41–75)
Himachal Pradesh <100 5 (3–8) <100 6 (3–9) 200 
(100–200)
34 (24–35) 300 
(200–300)
45 (30–53)
Jammu and Kashmir <100 2 (1–3) <100 2 (1–3) 200 
(100–200)
12 (8–12) 300 
(200–300)
15 (10–19)
Jharkhand 200 
(100–300)
4 (1–8) 200 
(100–400)
4 (2–9) 1200 
(800–1200)
29 (20–30) 1500 
(1000–1900)
37 (23–47)
Karnataka 100 
(100–300)
3 (1–5) 200 
(100–300)
3 (2–5) 1000 
(700–1100)
19 (13–20) 1300 
(900–1600)
24 (16–30)
Kerala <100 2 (1–4) <100 2 (1–4) 300 
(200–300)
12 (9–13) 400 
(300–500)
16 (11–20)
Madhya Pradesh 900 
(300–1800)
11 (4–22) 1000 
(400–2000)
12 (5–25) 6400 
(4600–6700)
80 (57–84) 8200 
(5300–10 400)
103 (66–130)
Maharashtra 200 
(100–400)
2 (1–4) 200 
(100–400)
2 (1–4) 1200 
(800–1200)
12 (8–12) 1500 
(1000–2000)
15 (10–20)
Northeast <100 5 (2–10) 200 
(100–300)
9 (4–19) 1000 
(700–1100)
61 (43–64) 1300 
(800–1600)
75 (49–93)
Odisha 300 
(100–600)
7 (3–15) 300 
(100–600)
8 (3–17) 2100 
(1500–2200)
54 (38–56) 2700 
(1700–3400)
69 (44–87)
Punjab <100 4 (2–7) <100 4 (2–8) 500 
(400–600)
24 (17–25) 700 
(500–900)
32 (21–40)
Rajasthan 500 
(200–1000)
7 (3–13) 600 
(300–1200)
8 (3–15) 3900 
(2800–4100)
50 (35–52) 5000 
(3300–6300)
64 (42–80)
Tamil Nadu 100 
(100–300)
2 (1–5) 100 
(100–300)
3 (1–6) 900 
(700–1000)
16 (11–17) 1200 
(800–1600)
21 (13–28)
Union territories <100 3 (1–5) <100 3 (2–6) <100 17 (12–18) <100 23 (15–28)
Uttar Pradesh 2000 
(900–3900)
9 (4–18) 2200 
(1000–4400)
10 (5–20) 14 700 
(10 400–15 300)
68 (48–71) 18 900 
(12 300–23 600)
88 (57–109)
Uttarakhand <100 4 (1–7) <100 4 (2–8) 300 
(200–300)
27 (19–29) 300 
(200–400)
35 (23–45)
West Bengal 300 
(200–600)
4 (2–8) 400 
(200–700)
5 (2–9) 2300 
(1600–2400)
30 (21–31) 3000 
(2000–3600)
38 (25–47)
(Table 3 continues on next page)
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morbidity and mortality were based on those for 
pathogen­specific meningitis.1
Population data
Sources of demographic and population data for each 
state are described in table 1. We used census data for 
India from 2001 and 2011 to estimate annual populations 
at risk. For years where child population data were not 
available, we used census data to estimate annual 
population growth rates to interpolate and extrapolate the 
state­level child population. We then normalised popu­
lation data to sum to the total national UN population 
estimates for India. The Sample Registration System 
(SRS) for India was used to pre pare annual child mortality 
estimates for each state.7 Since no state­level paediatric 
HIV prevalence estim ates are available, we assumed the 
same unpublished annual national HIV prevalence from 
UNAIDS for each state (Mahy M, UNAIDS, personal 
communication).
Adjustment for Hib vaccine use
Pathogen­specific burden estimates were calculated 
assuming no vaccine use. We then adjusted these 
estimates using estimates of Hib vaccine efficacy against 
invasive Hib disease18 and state­specific vaccine cov­
erage estimates to account for the impact of Hib vac­
cine use. Since no subnational estimates of Hib 
vac cine coverage are publicly available, we used coverage 
estimates for the third dose of diphtheria­tetanus­pertussis 
vaccine (DTP3) from subnational surveys, including the 
NFHS and the Annual Health Survey (AHS), as proxies 
for coverage with three doses of Hib vaccine. In the year of 
Hib vaccine introduction, we prorated coverage estimates 
to account for the month when the Hib vaccine was 
introduced. Linear inter polation was used when data were 
missing for relevant years. Our model accounts for 
indirect protection afforded by the Hib vaccine in the first 
years following introduction using the same methods 
previously reported.18 We assumed no children in India 
received PCV before 2015, since its use in the nat­
ional immunisa tion programme began only in 2017 in 
selected states.
Reporting
India is a large and sociodemographically diverse coun­
try, comprising 29 states and seven union territories. For 
the purpose of this analysis, we used six geographic­
ally contiguous and socioeconomically distinct regions: 
north, east, northeast, central, west, and south. For state­
level reporting, union territories, except for Delhi, and 
states with fewer than 1500 total child deaths, except for 
Goa, have been grouped as “northeast” and “other” on 
the basis of their location (table 2). Telangana separated 
from Andhra Pradesh in June, 2014. We projected 
population and mortality data for Andhra Pradesh and 
modelled Hib and pneumococcal disease burden for 
Andhra Pradesh and Telangana together for 2014 and 
2015. We also report on the pathogen­specific burden 
estimates together for five regions and eight states that 
are socioeconomically less developed than others in 
India (Empowered Action Group [EAG] states) plus 
Assam (table 2). Health indicators in Assam are often 
reported together with EAG states given its large size and 
similar development challenges.
Pathogen­specific mortality and incidence per 
100 000 children aged 1–59 months for each year are 
NPNM deaths 
(UR)
NPNM 
mortality 
rate (UR)
Meningitis 
deaths (UR)
Meningitis 
mortality 
rate (UR)
Pneumonia 
deaths (UR)
Pneumonia 
mortality 
rate (UR)
Total 
pneumococcal 
deaths (UR)
Total 
pneumococcal 
mortality rate 
(UR)
(Continued from previous page)
Regions
Central 3600 
(1600–7100)
9 (4–18) 4000 
(1800–8000)
10 (4–20) 26 500 
(18 800–27 600)
66 (47–69) 34 100 
(22 100–42 700)
85 (55–106)
East 1700 
(800–3300)
6 (2–11) 1900 
(800–3700)
6 (3–12) 12 200 
(8700–12 700)
40 (29–42) 15 800 
(10 300–19 600)
52 (34–65)
North 400 
(200–700)
4 (2–7) 400 
(200–800)
5 (2–8) 2700 
(1900–2800)
27 (19–28) 3500 
(2300–4300)
36 (24–44)
Northeast 500 
(200–1100)
10 (4–21) 700 
(300–1400)
13 (5–26) 4400 
(3100–4600)
85 (61–89) 5600 
(3600–7100)
108 (69–137)
South 600 
(300–1100)
3 (1–6) 600 
(300–1300)
3 (1–6) 4100 
(2900–4300)
20 (14–21) 5300 
(3400–6700)
26 (17–33)
West 500 
(200–1000)
3 (1–6) 500 
(200–1100)
3 (2–7) 3400 
(2400–3600)
21 (15–22) 4500 
(2900–5600)
28 (18–35)
National 7200 
(3200–14 300)
6 (3–12) 8200 
(3600–16 200)
7 (3–13) 53 300 
(37 800–55 500)
44 (31–46) 68 700 
(44 600–86 000)
56 (37–71)
Rates are cases or deaths per 100 000 children aged 1–59 months. NPNM=non-pneumonia, non-meningitis. UR=uncertainty range. *Burden among children with HIV 
infection included in the appendix (pp 22–41).
Table 3: Streptococcus pneumoniae mortality in Indian children aged 1–59 months without HIV infection* in 2015
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reported. Reported results are rounded and reported with 
three significant digits or fewer; precision was not provided 
for fewer than 100 cases or deaths. Higher precision 
is provided in the appendix (pp 22–41). Morbidity and 
mortality estim ates, unless otherwise specified, are given 
for children without HIV infection. Mortality and in­
cidence estimates associated with pneumococcal and Hib 
disease among children with HIV infection are provided 
in the appendix (pp 22–41).
Role of the funding source
The sponsor of this study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, or the decision to submit for publication. 
All authors had full access to all the data used in the 
study and the corresponding author had final responsi­
bility for the decision to submit for publication.
Results
Our literature review yielded only two studies that reported 
on the distribution of pathogens among children admitted 
to hospital with meningitis.9,10 An additional 33 studies 
from Asia providing data about the distribution of 
meningitis cases by cause were identified. We found no 
studies reporting on pneumococcal meningitis case 
fatality in India and only three studies reporting on Hib 
meningitis case fatality in India.11–13 Several additional 
studies from epidemiologically relevant settings con­
tributed data to estimates of pathogen­specific meningitis 
case fatality (appendix pp 5–8). The literature review 
also yielded two studies with data about the ratio of 
pneumococcal NPNM cases to pneumococcal meningitis 
cases from India.14,15
In 2015, 68 700 (uncertainty range [UR] 44 600–86 000) 
pneumococcal deaths and 15 600 (9800–21 500) Hib deaths 
were estimated to have occurred in children aged 
1–59 months in India. In this age group, among deaths 
categorised as being related to HIV/AIDS in India, we 
estimate that 1000 (UR 600–1200) deaths were caused 
by pneumococcal infection and fewer than 100 by Hib 
infection. At the national level, pneumococcal deaths 
declined by 58% (UR 22–78) since 2000, when there were 
166 000 (UR 110 000–198 000) estimated pneumococcal 
deaths. Hib deaths declined by 81% (UR 59–91) during the 
same time period; in 2000, there were an estimated 
82 600 (UR 52 300–112 000) Hib deaths. Despite substantial 
reductions in mortality, pneumococcus accounted for 14% 
(UR 9–17) and Hib for 3% (UR 2–4) of all deaths among 
children aged 1–59 months in India.
There were regional differences in pneumococcal and 
Hib mortality in India in 2015. Approximately 50% of 
pneumococcal deaths (34 100 [UR 22 100–42 700]) and 
65% of Hib deaths (10 300 [6500–14 100]) were estimated 
to have occurred in the central region, which accounted 
for only 33% of the child population in that year. 
75% of pneumococcal deaths (51 600 [33 400–64 600]) and 
83% of Hib deaths (13 000 [8100–17 800]) in 2015 occurred 
in the eight EAG states and Assam, which together 
account for 55% of the child population younger than 5 
years. The northeast region had the highest estimated 
Figure 2: Mortality rates for Streptococcus pneumoniae (A) and Haemophilus influenzae type b (B) in 2015 by state
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NPNM 
deaths 
(UR)
NPNM 
mortality 
rate (UR)
Meningitis 
deaths (UR)
Meningitis 
mortality 
rate (UR)
Pneumonia 
deaths (UR)
Pneumonia 
mortality 
rate (UR)
Total 
pneumococcal 
deaths (UR)
Total 
pneumococcal 
mortality rate 
(UR)
States
Andhra Pradesh <100  100 
(100–200)
2 (1–3) 400 
(300–500)
6 (4–8) 500 
(300–700)
8 (5–11)
Assam <100 0 (0–0) 200 
(100–300)
6 (2–9) 600 
(400–700)
16 (11–21) 800 
(500–1100)
22 (13–30)
Bihar <100 0 (0–0) 200 
(100–200)
1 (0–2) 500 
(300–600)
3 (2–4) 600 
(400–900)
4 (3–6)
Chhattisgarh <100 0 (0–0) <100 3 (1–4) 200 
(200–300)
8 (6–11) 300 
(200–400)
11 (7–15)
Delhi <100 0 (0–0) <100 0 (0–0) <100 1 (1–1) <100 1 (1–2)
Goa <100 0 (0–0) <100 0 (0–0) <100 0 (0–0) <100 0 (0–0)
Gujarat <100 0 (0–0) <100 1 (0–1) 100 
(100–200)
2 (1–3) 200 
(100–200)
3 (2–4)
Haryana <100 0 (0–0) <100 1 (0–1) <100 2 (2–3) <100 3 (2–4)
Himachal Pradesh <100 0 (0–0) <100 5 (3–7) <100 14 (10–19) 100 
(100–100)
19 (13–26)
Jammu and Kashmir <100 0 (0–0) <100 0 (0–0) <100 1 (0–1) <100 1 (1–1)
Jharkhand <100 0 (0–0) <100 1 (0–2) 100 
(100–200)
3 (2–4) 200 
(100–200)
4 (2–5)
Karnataka <100 0 (0–0) <100 0 (0–0) <100 1 (1–1) <100 1 (1–1)
Kerala <100 0 (0–0) <100 0 (0–0) <100 1 (0–1) <100 1 (0–1)
Madhya Pradesh <100 0 (0–0) 100 
(0–200)
1 (1–2) 300 
(200–400)
4 (3–5) 400 
(300–600)
5 (3–7)
Maharashtra <100 0 (0–0) 200 
(0–300)
2 (0–3) 600 
(400–800)
6 (4–8) 800 
(500–1100)
8 (5–11)
Northeast <100 0 (0–0) 100 
(0–200)
8 (3–13) 400 
(300–500)
23 (16–30) 500 
(300–700)
31 (19–43)
Odisha <100 0 (0–0) 300 
(0–400)
7 (3–11) 800 
(600–1100)
21 (15–27) 1110 
(700–1500)
28 (17–39)
Punjab <100 0 (0–0) <100 1 (0–1) <100 2 (1–3) <100 3 (2–4)
Rajasthan <100 0 (0–0) <100 1 (0–1) 200 
(100–200)
2 (2–3) 300 
(200–300)
3 (2–4)
(Table 4 continues on next page)
Figure 3: Burden of Streptococcus pneumoniae (A) and Haemophilus influenzae type b (B) deaths and mortality by state in 2015 
Size of bubble indicates absolute number of pathogen-specific deaths. Y-axis shows number of children aged 1–59 months living in each state.
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pneumococcal mortality in 2015, with approximately 
108 (UR 69–137) deaths per 100 000 children aged 
1–59 months, more than four times the pneumococcal 
mortality in the south region (26 [17–33]), which had the 
lowest pneumococcal mortality rate in 2015. The central 
(26 [UR 16–35]) and northeast (25 [15–34]) regions 
had the highest Hib mortality in 2015. Pneumococcal 
mortality rates decreased in all regions between 2000 and 
2015; however, compared with all other regions, the 
northeast region had the smallest declines (figure 1). 
Hib mortality rates in all regions declined by between 
57% (northeast region) and 94% (north region) between 
2000 and 2015 (figure 1).
State­level pathogen­specific deaths and mortality rates 
in 2015 are provided for pneumococcal infection in 
table 3 and figure 2A, and figure 3, and for Hib in table 4, 
figure 2B, and figure 3. Uttar Pradesh, the most populous 
state in India, ac counting for around 18% of the 
population younger than 5 years, had the highest number 
of pneumococcal and Hib deaths each year between 
2000 and 2015. An estimated 18 900 (UR 12 300–23 600) 
pneu mococcal deaths occurred in Uttar Pradesh in 2015, 
representing 28% of all pneumococcal deaths in 
that year, while 9300 (5900–12 700) Hib deaths occurred 
in the state, representing 60% of all Hib deaths in 
India in 2015. In 2000, Uttar Pradesh had the 
highest pneumococcal mortality (201 [UR 136–237] 
per 100 000 children aged 1–59 months) and Madhya 
Pradesh had the highest Hib mortality (99 [61–137] 
per 100 000 children aged 1–59 months). However, 
pneum ococcal mortality rates in Meghalaya were higher 
than in all other states from 2007 onwards, as was Hib 
mortality from 2009 onwards, and Meghalaya continued 
to have the highest mortality rates for both pathogens 
through to 2015.
Of the three syndromes associated with pneumo coccal 
and Hib infection, pneumonia accounted for the greatest 
burden of pathogen­specific mortality in India and in 
every state between 2000 and 2015. Pneumonia accounted 
for 78% (53 300 [UR 37 800–55 500]) of the all­syndrome 
pneumococcal deaths estimated in 2015, whereas 
meningitis accounted for 12% (8200 [3600–16 200]) 
and NPNM accounted for 11% (7200 [3200–14 500]). 
To be able to compare our findings with other published 
pneumococcal mortality estimates, we estimated there 
were 76 700 (UR 54 400–79 900) pneumococcal pneumo­
nia deaths, 11 800 (5600–22 700) meningitis deaths, 
and 7200 (3400–13 800) NPNM deaths in children aged 
1–59 months in 2010. Of the estimated Hib deaths in the 
same year, 74% (11 600 [UR 8200–15 300]) were due to 
pneumonia, 25% (4000 [1600–6100]) due to meningitis, 
and less than 1% (<100) due to NPNM.
NPNM 
deaths 
(UR)
NPNM 
mortality 
rate (UR)
Meningitis 
deaths (UR)
Meningitis 
mortality 
rate (UR)
Pneumonia 
deaths (UR)
Pneumonia 
mortality 
rate (UR)
Total 
pneumococcal 
deaths (UR)
Total 
pneumococcal 
mortality rate 
(UR)
(Continued from previous page)
Tamil Nadu <100 0 (0–0) <100 0 (0–0) <100 1 (0–1) <100 1 (0–1)
Union Territories <100 0 (0–0) <100 1 (0–1) <100 3 (2–3) <100 3 (2–5)
Uttar Pradesh <100 0 (0–0) 2400 
(1000–3600)
11 (5–17) 6900 
(4900–9100)
32 (22–42) 9300 
(5900–12 700)
43 (27–59)
Uttarakhand <100 0 (0–0) <100 1 (0–1) <100 2 (1–3) <100 3 (2–4)
West Bengal <100 0 (0–0) <100 1 (0–1) 200 
(100–200)
2 (2–3) 200 
(200–300)
3 (2–4)
Regions
Central <100 0 (0–0) 2600 
(1100–4000)
7 (3–10) 7600 
(5400–10 000)
19 (13–25) 10 300 
(6500–14 100)
26 (16–35)
East <100 0 (0–0) 500 
(200–900)
2 (1–3) 1600 
(1100–2100)
5 (4–7) 2100 
(1300–2900)
7 (4–10)
North <100 0 (0–0) <100 1 (0–1) 200 
(200–300)
2 (2–3) 300 
(200–400)
3 (2–4)
Northeast <100 0 (0–0) 300 
(100–500)
6 (2–10) 1000 
(700–1300)
18 (13–24) 1300 
(800–1780)
25 (15–34)
South <100 0 (0–0) 200 
(100–300)
1 (0–1) 500 
(300–700)
2 (2–3) 700 
(400–900)
3 (2–5)
West <100 0 (0–0) 200 
(100–400)
1 (0–2) 700 
(500–900)
4 (3–6) 900 
(600–1300)
6 (4–8)
National <100 0 (0–0) 4000 
(1600–6100)
3 (1–5) 11 600 
(8200–15 300)
10 (7–13) 15 600 
(9800–21 500)
13 (8–18)
Rates are cases or deaths per 100 000 children aged 1–59 months. NPNM=non-pneumonia, non-meningitis. UR=uncertainty range. *Burden among children with 
HIV infection included in the appendix (pp 22–41).
Table 4: Haemophilus influenzae type b mortality in Indian children aged 1–59 months without HIV infection* in 2015
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As previously reported,1 we estimated pneumococcus 
to account for 34% (UR 24–36) and Hib to account for 
21% (15–28) of radiograph­confirmed pneumonia cases; 
we used those case­derived proportions as a proxy for 
the fraction of pneumonia deaths attributable to these 
two pathogens, in settings where PCV and Hib vaccine 
are not used.1 Our sensitivity analysis found that the 
proportion of radiograph­confirmed pneumonia that is 
pneumococcus could be as high as 51% (UR 15–87), 
in which case there could have been as many as 
102 000 (UR 62 200–110 000) estimated pneumococcal 
pneumonia deaths and therefore 118 000 (69 000–140 000) 
pneumococcal deaths in 2015. State­level pneumococcal 
pneumonia deaths based on this sensitivity analysis are 
provided in the appendix (pp 42–57).
We estimated 1·6 million (UR 1·2–1·9) cases of severe 
pneumococcal disease (ie, severe pneumococcal pneu­
monia, pneumococcal meningitis, and severe NPNM) in 
2015. There were 2·7 million (UR 2·0–3·1) estimated 
severe pneumococcal cases in 2000, representing a 
reduction of almost 40%. Uttar Pradesh (367 000 
[UR 271 000–428 000]), Bihar (238 000 [177 000–276 000]), 
and Maharashtra (149 000 [111 000–171 000]) had the 
highest numbers of estimated severe pneumococcal 
cases in 2015. Madhya Pradesh (1767 [UR 1304–2068]), 
Uttar Pradesh (1697 [1254–1982]), and Bihar (1648 
[1223–1912]) had the highest incidence of severe 
pneumococcal disease per 100 000 children aged 
1–59 months in 2015. Severe pneumo coccal disease in 
India manifests primarily as severe pneumonia. There 
were 1·6 million (UR 1·2–1·8) estimated cases of severe 
pneumococcal pneumonia in 2015, accounting for more 
than 97% of all severe pneumococcal disease.
By 2015, severe Hib disease had declined in India to 
236 000 cases (UR 138 000–468 000), a substantial decline 
from the 883 000 (517 000–1 750 000) estimated cases in 
2000. More than 73% of severe Hib cases in 2015 occurred 
in three states that together only accounted for 30% of 
the child population in that same year: Uttar Pradesh 
(UR 120 000 [703 000–238 000]), Maharashtra (39 000 
[22 900–78 200]), and Odisha (13 600 [7900–27 100]).
Discussion
We estimated the comprehensive (ie, including all 
relevant syndromes) subnational pneumococcal and 
Hib morbidity and mortality burden for children aged 
1–59 months in India. Our analysis found that, even 
before introduction of the PCV or Hib vaccine, 
pneumococcal and Hib deaths in children had declined 
substantially since 2000. Despite sub stantial reductions 
in mortality, pneumococcus accoun ted for 14% (UR 9–17) 
and Hib for 3% (UR 2–4) of all deaths among children 
aged 1–59 months in India. These deaths are largely 
preventable with specific interventions such as vaccines 
that prevent the occurrence of cause­specific disease and 
with early and effective treatment. These estimates can be 
used to monitor progress towards achieving child survival 
targets and inform the impact of disease prevention and 
treatment strategies.
The reduction in deaths from these two pathogens 
before the introduction and widespread use of the PCV 
and Hib vaccine reflects overall child survival trends in 
India during this period.19 The launch of the National Rural 
Health Mission (NRHM) in 2005, now the National Health 
Mission (NHM), has helped to expand and improve 
primary maternal and child health services in the country, 
which is likely to have contributed to improvements in 
overall child survival.20,21 Our model quantified the 
accelerated decline in Hib deaths after 2012, during which 
the Hib vaccine was introduced in many states. Uttar 
Pradesh, which accounted for approximately 60% of Hib 
deaths, was the last state to initiate routine use of the 
Hib vaccine in December, 2015.
A disproportionate number of pneumococcal and Hib 
deaths continue to occur in states located in the eastern 
and central regions. The states in these two regions, 
excluding West Bengal, comprise the EAG states. Dis­
parities between EAG states (inclusive of Assam) and 
non­EAG states, represented by the difference be­
tween pneu mococcal and Hib mortality between these 
two groups, diminished between 2000 and 2015. The 
NHM’s efforts have been most intensive in EAG states and 
in states in the northeast region, including Assam. This is 
likely to have contributed to a reduction in these disparities 
over time. The estimates imply that introduction of the 
Hib vaccine in many EAG states and Assam throughout 
2014 and 2015 has contributed to further minimisation of 
the differences in Hib mortality rates between these 
two groups of states (figure 1). The recent subnational 
introduction of PCV­13 in 2017 and its projected national 
rollout over the coming years is expected to further reduce 
differences in pneumococcal and all­cause mortality.
Similar to global burden estimates, pneumonia domin­
ated the syndromic distribution of deaths associated 
with pneumococcus and Hib in India. As a result, 
disease burden estimates for both pathogens are highly 
sensitive to changes in estimates for all­cause pneumonia 
mortality and the fraction of pneumonia deaths 
associated with each pathogen. In the probe approach, 
we used estimates of the proportion of radiograph­
confirmed pneumonia cases caused by pneumococcus 
and Hib as proxy values for the proportion of pneumonia 
deaths associated with each pathogen. This approach 
results in the inherent inference that the case fatality 
estimates for radiograph­confirmed pneumonia caused 
by pneumococcus, Hib, and non­pneumococcus or non­
Hib are identical, which is likely to be incorrect. Without 
access to timely and effect ive antibiotics, the case fatality 
for bacterial causes of pneumonia is likely to be higher 
than that for non­bacterial pneumonia. Most deaths 
from pneumonia in India occur in the community, 
rather than in health­care facilities, indicating that many 
individuals who develop pneumonia probably do not 
have access to antibiotics.22 As a result, our approach has 
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a direction of bias that is likely to underestimate state­
level mortality rates and deaths from pneumococcal and 
Hib pneumonia.
The vaccine probe approach also requires adjustment 
for incomplete vaccine efficacy. As a proxy for vaccine­
type pneumococcal pneumonia efficacy in children, we 
used efficacy against vaccine­type invasive pneumococcal 
diseases, which is likely to be higher than vaccine­type 
pneumococcal pneumonia efficacy. If true, this approach 
also underestimates the contribution of pneumococcus 
to deaths from pneumonia. We did a sensitivity analysis 
using data from a PCV clinical trial with a pathogen­
specific pneumonia efficacy outcome done in an elderly 
population in the Netherlands23 to assess the magnitude 
of potential underestimation. We found that deaths 
from pneumococcal pneumonia could be as much as 
50% higher than our current estimates.1 Others have 
included this adjustment in their base case model for 
global pneumococcal pneumonia mortality estimates;24 
we report the results of our sensitivity analysis at the 
state level in the appendix (pp 42–57).
Our subnational model allows us to account for 
differences in vaccine coverage between states. Without 
accounting for subnational differences in vaccine cov­
erage, the impact of new vaccines on pathogen­specific 
disease would be biased. In the case of the Hib vaccine, 
which was first used in states with low child mortality, 
accounting for vaccine use at the state level restricts the 
degree to which the effects of the Hib vaccine are 
overestimated in the years following the introduction 
of vaccine. We used state­level DTP3 coverage from 
two different surveys as a proxy for state­level Hib vaccine 
coverage. In the routine immunisation programme in 
India, the Hib vaccine is delivered together with four other 
antigens (ie, DTP and hepatitis B) as a pentavalent vaccine.
The 13­valent PCV was introduced in 2017 in three states 
with relatively high child mortality. Researchers who did 
an invasive pneumococcal disease surveillance study 
between 2011 and 2015 in India concluded that the 
13­valent PCV product includes serotypes responsible for 
74% of invasive pneumococcal disease nationwide.25 
Although subnational PCV coverage estimates in the 
private sector have been published for 2012,26 we did not 
use these estimates in our model as the overall national 
coverage was reported to be lower than 1%. Additionally, 
those who received PCV in the private sector are probably 
already at low risk of pneumococcal disease and mortality 
than those without access to PCV in the private sector.
Subnational pneumococcal pneumonia morbidity and 
mortality burden estimates for 2010 have been published.6 
We prepared annual estimates of subnational pneumo­
coccal and Hib deaths by syndrome between 2000 and 
2015 so that we could compare our estimates with the 
published literature. In 2010, we estimated there were 
76 700 (UR 54 400–79 900) deaths from pneumococcal 
pneumonia in Indian children aged 1–59 months 
(appendix pp 29–34), whereas Farooqui and colleagues6 
estimated 105 100 (UR 91 100–120 000) deaths from 
pneumococcal pneumonia. Although there are quanti­
tative differences between our estimates and those of 
Farooqui and colleagues6 at the state level, the rank order 
of states based on deaths from pneumococcal pneumonia 
is similar across the two models (ie, the four states with 
the greatest burden are the same in both models), 
indicating that the use of either set of estimates for state­
specific PCV prioritisation would lead to the same 
conclusions. The conceptual approaches used to prepare 
estimates of pneumococcal pneumonia deaths differ 
between the two models, which largely account for the 
quantita tive discrepancies between the estimates 
prepared by Farooqui and colleagues and our estimates. 
A state­level comparison of results from both models and 
the details of the different approaches is provided in the 
appendix (p 20).
India has previously introduced new vaccines into the 
national immunisation programme in a phased manner. 
The approach for state selection has differed by vaccine, 
and decision makers might consider a range of factors for 
which subnational data are available, including disease 
burden, potential vaccine impact, indicators of equity, 
health­system readiness, and routine immunisation cov­
er age. India has usually initiated introductions in states 
and union territories with relatively strong health systems. 
However, the introduction of PCV marked a shift in 
this approach, prioritising on the basis of child mortality 
rather than health­system strength or vaccine coverage. 
The availability of subnational estimates enables evidence­
based strategies for state prioritisation; in particular, such 
estimates allow India to develop equity­focused and 
impact­focused approaches to PCV rollout and subsequent 
new vaccine introductions.
Policy makers increasingly consider mortality and mor­
bidity burden estimates together when making decisions 
about the introduction of new vaccines. Mor bidity burden 
estimates are also important variables in vaccine cost­
effectiveness analyses.27 Until now, sub national morbidity 
burden estimates for pneumococcus have only been 
available for severe pneumonia. Although this syndrome 
accounts for a large fraction of severe pneumococcal 
diseases, bacterial meningitis cases in India often result 
in severe, long­term neurological impairments.28,29 These 
morbidity burden estimates are necessary for cost­of­
illness assessments. To contribute to these efforts, we 
prepared subnational pneumococcal and Hib morbidity 
estimates for each syndrome associated with these 
pathogens.
In addition to the challenges associated with the vaccine 
probe approach described above, our approach for estim­
ating the subnational burden of pneumococcal and Hib 
disease in India has other limitations. Although our 
estimates inherently account for state­level disease risk 
factors and access to care differences, additional dis parities 
within states and populations remain. Our models do not 
account for these disparities. All­cause child mortality 
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estimates are now available with higher spatial resolution 
(ie, at the district level).30 These estim ates could serve as 
the basis for future pathogen­specific mortality estimates 
at the district level in India. However, such estimates 
would require additional district­level input data, including 
PCV and Hib vaccine coverage. This information would be 
useful for future pneumococcal disease burden estimates, 
given the district­wise intro duction strategy for PCV.
Another limitation of our model is the continued 
reliance on verbal autopsy data for all­cause pneumonia 
and meningitis deaths.7 Verbal autopsy data are susceptible 
to misclassification and other challenges that have been 
described extensively.31,32 These challenges are especially 
relevant for deaths from non­specific syndromes such as 
pneumonia. Nationally representative cause­of­death data 
that have been directly measured, as opposed to modelled 
estimates, are now available.33 Pneumococcal and Hib 
disease burden estimates based on these cause­of­death 
data could complement the estimates provided here. 
Additionally, strengthened vital registration systems and 
medical cause of death reporting in India would help 
improve confidence in cause­specific disease burden 
estimates.
We used data from India or its regional neighbours 
wherever possible. Population­at­risk and demographic 
data came largely from Indian Government sources. The 
pathogen­specific pneumonia models use data from 
vaccine clinical trials done in several countries around 
the world. The implications, assumptions, and possible 
consequential underestimation or overestimation from 
the pathogen­specific component of the model are 
discussed elsewhere.1 Another limitation of our estimates 
is the absence of data from India about pathogen­specific 
meningitis and NPNM. We therefore relied on data from 
studies done in geographically and epidemiologically 
relevant settings. Additional pathogen­specific data from 
observational studies done in India would help improve 
disease burden estimates.
Our subnational estimates of mortality and morbidity 
caused by pneumococcus and Hib suggest that India has 
made substantial progress in reducing mortality and 
morbidity from these diseases in the past 15 years and that 
the recent Hib vaccine introductions have further 
accelerated these reductions. The introduction and ex­
panded use of these vaccines as planned by the govern­
ment has the potential to substantially accelerate the 
reduction of childhood pneumococcal and Hib mor­
bidity and mortality towards meeting the Sustainable 
Development Goal child survival targets by 2030.
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